Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | CPB1 | P15086 | 1/20 | 0.33 |
| ▸ | CPB2 | Q96IY4 | 1/20 | 0.33 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.31 |
| ▸ | CPT2 | P23786 | 1/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23539820 | 0.78 | CYP2D6 (0.33) | CYP2D6CYP2C19FFAR1CPT2TDP1 | |
| SCHEMBL4077716 | 0.77 | GRM4 (0.38) | CYP2D6CYP2C19KDM4C | |
| SCHEMBL4936016 | 0.77 | KDM4E (0.48) | KDM4ECYP2D6CYP2C19 | |
| SCHEMBL5489345 | 0.77 | SIGMAR1 (0.44) | CYP2D6CYP2C19KDM4C | |
| SCHEMBL4334873 | 0.76 | CYP2D6 (0.34) | CYP2D6CYP2C19KDM4C | |
| SCHEMBL5807159 | 0.75 | ALDH1A1 (0.43) | CYP2D6CYP2C19FFAR1CPT2TDP1 | |
| SCHEMBL30096633 | 0.74 | ALDH1A1 (0.32) | — | |
| SCHEMBL11982017 | 0.72 | KDM4E (0.43) | KDM4ECYP2D6CYP2C19 | |
| SCHEMBL28035771 | 0.72 | KDM4E (0.43) | KDM4ECYP2D6CPB1CPB2FFAR1 | |
| SCHEMBL22035035 | 0.71 | CYP2D6 (0.31) | CYP2D6CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | VITAE PHARMACEUTICALS, INC. | 2010-12-16 | — | — | US | disclosed |
| EP-2167609-A1 | RENIN INHIBITORS | Vitae Pharmaceuticals, Inc. (US) | 2010-03-31 | — | — | EP | disclosed |
| WO-2009096996-A1 | RENIN INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2009-08-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317697-A1 | Renin Inhibitors | REN, ACE, SERPINB1 | KDM4E 3763/4885CYP2D6 1886/4885CYP2C19 2600/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.